Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: entecavirDrug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT00940485
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 54
- Registration Number
- NCT00940875
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 190
- Registration Number
- NCT00937560
- Locations
- 🇳🇱
Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde, Leidschendam, Netherlands
🇮🇹Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica, Campobasso, Molise, Italy
🇫🇷Clinique Tivoli; Sce Radiotherapie, Bordeaux, France
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT00934648
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: RO4998452
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT00933972
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00934856
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 281
- Registration Number
- NCT00930514
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT00929240
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 383
- Registration Number
- NCT00927082
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT00925769
© Copyright 2025. All Rights Reserved by MedPath